KRAS and non-small cell lung carcinoma: A phase II trial under the umbrella of CodeBreaK 100 evaluated 124 patients with KRAS G12C-mutant advanced NSCLC who had progressed on prior platinum-based chemotherapy and programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1) therapy, and who had measurable disease.